Bempedoic Acid (Nexletol) for Lowering LDL-Cholesterol

Date: April 6, 2020 Issue #:  1595Summary:  The FDA has approved the oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid for use alone (Nexletol– Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe(Nexlizet) as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-cholesterol (LDL-C). Bempedoic acid is the first ACL inhibitor to be approved in the US.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: alirocumab Altoprev Atorvastatin bempedoic acid Cholesterol Cholestyramine Colesevelam Colestid Colestipol Crestor evolocumab Ezetimibe Ezetrol Fenofibrate Flolipid Fluvastatin Gemfibrozil icosapent ethyl Lescol Lipit Source Type: research